ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2026
Astragalus Polysaccharides Target the Wnt/β-catenin Pathway to Suppress Malignant Behavior in Hepatocellular Carcinoma.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Despite some improvement in patient prognosis, hepatocellular carcinoma (HCC) remains a prevalent malignant tumor with disappointingly low overall survival rates. This study aims to investigate the inhibitory effects of astragalus polysaccharides (APs) on the malignant biological behavior of HCC and its underlying mechanisms, aiming to provide new strategies and theoretical foundations for HCC treatment. Materials and Methods: The inhibitory effects of APs on HCC were assessed using animal models and in vitro experiments. In animal models, different doses of APs were tested for their anti-tumor efficacy. In vitro, CCK-8 and Transwell assays assessed APs effects on HCCLM3 and HuH7 cell malignancy. Western blot analyzed Wnt/β-catenin pathway proteins and epithelial-mesenchymal transition (EMT) markers in APs-treated HCC cells. Rescue experiments confirmed APs-mediated inhibition of HCC behavior via Wnt/β-catenin signaling. Results: Animal experiments demonstrated that APs could effectively inhibit HCC development, with its inhibitory effect becoming stronger as the dose of APs increased. The in vitro data revealed that APs primarily inhibited the Wnt/β-catenin signaling pathway by downregulating β-catenin and p-GSK3β levels while increasing p-β-catenin levels, thereby inhibiting HCC malignancy. APs also regulated the expression of vimentin, N-cadherin, and E-cadherin-EMT markers. Moreover, in vitro rescue experiments indicated that APs induced apoptosis in HCC cells and inhibited their migration and invasion, which could be counteracted by a Wnt/β-catenin pathway activator. Conclusion: APs effectively curb the growth, spread, and invasiveness of HCC cells by targeting the Wnt/β-catenin pathway, thereby opening up new possibilities for HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.